Linezolid S.A.L.F.

Linezolid, the active ingredient in Linezolid S.A.L.F., is an oxazolidinone presented as an injectable solution for intravenous use. It treats infections caused by susceptible Gram‑positive bacteria, including MRSA and VRE, in adult patients. GNH USA supplies Linezolid S.A.L.F. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linezolid is an oxazolidinone antibiotic indicated for several serious bacterial infections. - Skin and soft tissue infections: effective against susceptible Gram‑positive pathogens, reducing infection severity. - Community‑acquired pneumonia: treats pneumonia caused by susceptible organisms, improving respiratory function. - Hospital‑acquired pneumonia: active against resistant strains, aiding recovery in hospitalized patients. - Complicated skin and soft tissue infections: provides coverage for deep or extensive infections. - Infections caused by MRSA: offers an alternative to beta‑lactams for methicillin‑resistant Staphylococcus aureus. - Infections caused by VRE: active against vancomycin‑resistant Enterococcus species, facilitating infection control.

Linezolid may cause a range of adverse reactions.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools occurring during therapy. - Headache: transient cranial discomfort. - Vomiting: occasional emesis. - Metallic taste: altered taste perception. - Rash: mild skin erythema.

Serious or Rare Side Effects: - Thrombocytopenia: significant drop in platelet count requiring monitoring. - Anemia: reduction in hemoglobin levels. - Peripheral neuropathy: nerve damage presenting as tingling or numbness. - Serotonin syndrome: potentially life‑threatening reaction when combined with serotonergic agents. - Elevated liver enzymes: indication of hepatic stress. - Severe hypotension: marked drop in blood pressure during infusion.

Before initiating therapy, consider the following precautions. - Renal impairment: monitor renal function and adjust therapy as needed. - Hepatic impairment: assess liver enzymes regularly. - Concomitant serotonergic drugs: avoid due to risk of serotonin syndrome. - Hematologic monitoring: perform regular complete blood counts to detect thrombocytopenia or anemia. - Pregnancy and lactation: safety not established; weigh benefits against potential risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Linezolid interacts with several drug classes.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Selective serotonin reuptake inhibitors (SSRIs) and SNRIs: increased risk of serotonin syndrome. - Rifampin: markedly reduces linezolid plasma concentrations. - Anticonvulsants (e.g., phenytoin): may lower linezolid levels. - Tyramine‑rich foods: can precipitate hypertensive reactions.

Moderate Interactions (Monitor Closely): - Warfarin: potential alteration of INR, requiring closer monitoring. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase bleeding risk. - Digoxin: possible increase in serum digoxin levels. - Ethanol: may cause disulfiram‑like reactions. - Proton pump inhibitors: occasional effect on absorption, monitor efficacy.